abbv-400
mAbexperimentalADC
Clinical trial activity
13 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
8
Phase 3
3
Phase 4
0
Earliest trial started Oct 13, 2021 (NCT05029882)
Timeline
Indications
Studied for
- Biliary Tract Neoplasms · Phase 1
- Breast Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2/Phase 3
- Carcinoma, Ovarian Epithelial · Phase 1
- Colorectal Neoplasms · Phase 3
- Esophageal Neoplasms · Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 1
- Head and Neck Neoplasms · Phase 1
- Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Stomach Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 1
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Payload
- Monomethyl auristatin E
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068181 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07196644 | Phase 2 | Nov 25, 2025 | AbbVie |
| NCT07155187 | Phase 2/Phase 3 (Phase 3) | Nov 15, 2025 | AbbVie |
| NCT07023289 | Phase 2 | Aug 7, 2025 | AbbVie |
| NCT07005102 | Phase 2/Phase 3 (Phase 3) | Aug 3, 2025 | AbbVie |
| NCT06820463 | Phase 2 | Mar 26, 2025 | AbbVie |
| NCT06772623 | Phase 1/Phase 2 (Phase 2) | Mar 6, 2025 | AbbVie |
| NCT06628310 | Phase 2 | Dec 8, 2024 | AbbVie |
| NCT06614192 | Phase 3 | Nov 24, 2024 | AbbVie |
| NCT06464692 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2024 | AbbVie |
| NCT06107413 | Phase 2 | Nov 12, 2023 | AbbVie |
| NCT06084481 | Phase 1 | Nov 9, 2023 | AbbVie |
| NCT05029882 | Phase 1 | Oct 13, 2021 | AbbVie |
| NCT05982873 | N/A | — | AbbVie |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 13 | 13 | 4 | 2021 |
1 organizations
Page 1 / 1